Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance | Zendy

Isabelle Malet | Zendy; Francesca Alessandra Ambrosio | Zendy; Frédéric Subra | Zendy; Béatrice Herrmann | Zendy; Hervé Leh | Zendy; Marie-Christine Bouger | Zendy; Anna Artese | Zendy; Christine Katlama | Zendy; Carmine Talarico | Zendy; Isabella Romeo | Zendy; Stefano Alcaro | Zendy; Giosuè Costa | Zendy; Eric Deprez | Zendy; Vincent Cálvez | Zendy; AnneGeneviève Marcelin | Zendy; Olivier Delelis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance

Author(s) -

Isabelle Malet,

Francesca Alessandra Ambrosio,

Frédéric Subra,

Béatrice Herrmann,

Hervé Leh,

Marie-Christine Bouger,

Anna Artese,

Christine Katlama,

Carmine Talarico,

Isabella Romeo,

Stefano Alcaro,

Giosuè Costa,

Eric Deprez,

Vincent Cálvez,

AnneGeneviève Marcelin,

Olivier Delelis

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx529

Subject(s) - dolutegravir , elvitegravir , raltegravir , integrase , integrase inhibitor , virology , mutation , medicine , genetics , biology , human immunodeficiency virus (hiv) , gene , viral load , antiretroviral therapy

Dolutegravir, an integrase strand-transfer inhibitor (STI), shows a high genetic barrier to resistance. Dolutegravir is reported to be effective against viruses resistant to raltegravir and elvitegravir. In this study, we report the case of a patient treated with dolutegravir monotherapy. Failure of dolutegravir treatment was observed concomitant with the appearance of N155H-K211R-E212T mutations in the integrase (IN) gene in addition to the polymorphic K156N mutation that was present at baseline in this patient.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research